{"entity":{"id":"nct05607420","kind":"trial","name":"Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma","aka":[],"tldr":"A phase 1/2 trial of Alemtuzumab in hodgkin lymphoma and non-hodgkin lymphoma, run by Cellectis S.A., now recruiting.","summary":"Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma is a phase 1/2 interventional study registered as NCT05607420 by Cellectis S.A., with 80 participants planned, started 2022-11-01 and due to reach its primary completion in 2027-08. Interventions recorded: UCART20x22, CLLS52. Conditions listed: B-cell Non-Hodgkin Lymphoma (B-NHL). No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05607420","url":"https://clinicaltrials.gov/study/NCT05607420"}],"tags":["ctgov-ingest"],"related":[],"cancers":["hodgkin-lymphoma","non-hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["alemtuzumab"],"companies":["cellectis-s-a"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05607420","phase":"1/2","setting":"Open-label Dose-finding and Dose-expansion Study to Evaluate the Safety, Expansion, Persistence, and Clinical Activity of UCART20x22 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (B-NHL)","sponsor":"Cellectis S.A.","enrolled":80,"outcomes":[]},"route":"/trials/nct05607420/","neighbours":{"cancer":[{"id":"hodgkin-lymphoma","kind":"cancer","name":"Hodgkin lymphoma","route":"/cancers/hodgkin-lymphoma/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"drug":[{"id":"alemtuzumab","kind":"drug","name":"Alemtuzumab","route":"/drugs/alemtuzumab/"}],"company":[{"id":"cellectis-s-a","kind":"company","name":"Cellectis S.A.","route":"/companies/cellectis-s-a/"}]}}